Upstate Active Clinical Trials
Study Title:A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
What is the purpose of the study?This study involves research for the purpose of seeing how effective REGN2222 is at reducing medical visits for RSV infection when it is administered intramuscularly (IM), by inserting a needle into the muscle.
Upstate Institutional Review Board (IRB) Number:770394
Study Phase:Phase III
Patient Age Group:Children
Principal Investigator:Joseph B Domachowske
Who can I contact for more information?
Name: Jodi Halczyn